The latest industry information published by Credence Research “Global Opioid Induced Constipation Drugs industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the opioid induced constipation drugs industry was valued at USD 1,933.2 Mn in 2015, and is expected to reach USD 2,779.24 Mn by 2022, expanding at a CAGR of 4.6% from 2016 to 2022.
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs industry growth. The global opioid induced constipation drugs industry was valued at USD 1,933.2 Mn in 2014 and is expected to reach USD 2,779.2 Mn by 2022 with the industry growing at a CAGR of 4.6% during 2016-2022.
Browse the full report Opioid Induced Constipation Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 report at : http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated for OIC treatment. Among these, methylnaltrexone bromide holds the largest industry size and is expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone under the brandname Amitiza is indicated for treating OIC, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over the industry share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for various patient types such as pregnant women and patients less than 17 years of age. Thus, future approvals are expected to lead the industry.
North America is the dominant regional OIC drugs industry through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs industry in North America. On the other hand, Germany, UK, and Spain are the major countries setting the industry dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.
Request Free Sample : http://www.credenceresearch.com/sample-request/57737
On the basis of prescription type the industry is segmented into prescribed drugs and over the counter or OTC drugs. Constipation is never considered as a disease but a syndrome or a side effect; people are less likely to visit doctors to get prescription for constipation. Thus, the OIC drugs industry is dominated by over the counter prescription with 65.87% industry share in 2014. The OTC drug industry will continue to dominate the industry growing at the highest CAGR of 4.9% during 2016-2022.
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US